Denali therapeutics presents positive results from phase 1 and phase 1b studies of its lrrk2 inhibitor, biib122/dnl151, supporting late-stage development plans in parkinson's disease

South san francisco, calif., may 01, 2021 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for neurodegenerative diseases, today announced final results from phase 1 and phase 1b studies of its small molecule lrrk2 inhibitor, biib122/dnl151, which is being developed in collaboration with biogen as a potential treatment of parkinson's disease. safety and biomarker goals were met in both studies, supporting plans to advance biib122/dnl151 into late-stage clinical development in parkinson's disease by year-end 2021. the results will be presented at the international association of parkinsonism and related disorders virtual congress, being held may 1-4.
DNLI Ratings Summary
DNLI Quant Ranking